Life without Disease: THE PURSUIT OF MEDICAL UTOPIA

Life without Disease: The Pursuit of Medical Utopia

Volumn , Issue , 2023, Pages 1-180

  Schwartz, William B ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85184340694     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (71)

1. Rolleston HD. Some medical aspects of old age. London: Macmillan, 1922, 7.
2. Dubos R. The dreams of reason: Science and Utopias. New York:Columbia University Press, 1961, 64-56.
3. Drew EB. The health syndicate. Atlantic Monthly 1967;220(6):75-82.
4. Strickland SP. Politics, science, and dread disease. Cambridge, Mass.: Harvard University Press, 1972; National Institutes of Health Web page:www.nih.gov/news/budget.
5. Rettig RA, Marks E. The federal government and social planning for end-stage renal disease: past, present, and future. Santa Monica, Calif.: Rand, 1983.
6. Rettig RA. Origins of the medicare kidney disease entitlement: the social security amendments of 1972. Washington, D.C.: National Academy of Sciences, Institute of Medicine, 1990.
7. Rettig RA. The policy debate on patient care financing for victims of end stage renal disease. Law and Contemporary Problems 1976; 40(4): 196-230.
8. Tunis SR, Gelband H. Health care technology in the United States. Health Policy 1994;30:335-96.
9. Levit KR, Sensenig AL, Cowan CA, et al. National health expenditures, 1993. Health care financing review 1994;16(1):247-94.
10. Levit KR, Sensenig AL, Cowan CA, et al. National health expenditures, 1993. Health Care Financing Review 1994;16(1):247-94.
11. Schwartz WB, Mendelson DN. Hospital cost containment in the 1980s: hard lessons learned and prospects for the 1990s. New England Journal of Medicine 1991;324:1037-42.
12. Levit KR, Sensenig AL, Cowan CA et al. National health expenditures, 1993. Health Care Financing Review 1994;16(1):247-94.
13. Schwartz WB, Mendelson DN. Eliminating waste and inefficiency can do little to contain costs. Health Affairs 1994; 13(1):224-38.
14. Schwartz WB, Mendelson DN. Eliminating waste and inefficiency can do litde to contain costs. Health Mairs 1994;13(1):224-38.
15. Sparrow MK. Health care fraud control: the state of the art. Cambridge: Harvard, 1995.
16. Prager LO. Questions raised about impact of guidelines in Maine project. American Medical News 1996;39(21):1.
17. Aaron HJ. Serious and unstable condition: financing America’s health care. Washington, D.C.: Brookings Institution, 1991.
18. Schwartz WB, Mendelson DN. Eliminating waste and inefficiency can do litde to contain costs. Health Affairs 1994; 13 (1): 224-38.
19. Jensen GA, Morrisey MA, Gaffney S, Listón DK. The new dominance of managed care: insurance trends in the 1990s. Health Affairs 1997; 16 (1):125-36.
20. Mitka M. Market-driven match: most U.S. grads choose primary care. American Medical News 1996;39(14):1.
21. Schroeder SA. The latest forecast:managed care collides with physician supply. Journal of the American Medical Association 1994;272(3):239-40.
22. Schwartz WB, Mendelson DN. Physicians who have lost their malpractice insurance. Journal of the .American Medical Association 1989;262(10):1335-4-1.
23. Raichle ME. Visualizing the mind. Scientific American 1994;270(4):58-63.
24. Satava RM. Emerging medical applications of virtual reality: a surgeon’s perspective. Artificial Intelligence in Medicine 1996;6(4):281-88.
25. Schoenenberger AW, Bauerfeind P, Krestin GP, et al. Virtual colonoscopy with magnetic resonance imaging: in vitro evaluation of a new concept. Gastroenterology 1997;112(6): 1863-70.
26. Satava RM. Virtual reality and telepresence for military medicine. Computers in Biology and Medicine 1995;25(2);229-36.
27. Schwartz WB, Patil RS, Szolovitz P. Artificial intelligence in medicine:where do we stand? New England Journal of Medicine 1987;316:685-88.
28. Baxt WG. Use of an artificial neural network for the diagnosis of myocardial infarction. Annals of Internal Medicine 1991; 115(11):843-48.
29. Baxt WG, Skora J. Prospective validation of artificial neural network trained to identify acute myocardial infarction. Lancet 1996;347(8993):12-15.
30. Rubel EW, Stone JS. Stimulating hair cell regeneration: on a wing and a prayer. Nature Medicine 1996;2(10):1082-83.
31. Langer R and Vacanti JP. Artificial organs. Scientific .American. September 1995:130-33.
32. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385(6619):810-23.
33. Aaron HJ and Schwartz WB. The painful prescription: rationing hospital care. Washington, D.C.: Brookings Institution, 1984.
34. Aaron HJ, Schwartz WB. The painful prescription: rationing hospital care. Washington, D.C.: Brookings Institution, 1984, 102.
35. Aaron HJ, Schwartz WB. The painful prescription: rationing hospital care. Washington, D.C.: Brookings Institution, 1984, 102.
36. Dean M. British health rationing becomes explicit. Lancet 1995;346:1415.
37. Kassirer JP. Managing managed care’s tarnished image. New England Journal of Medicine 1997;337(5):338-39.
38. Jollis JG, DeLong ER, Peterson ED, et al. Outcome of acute myocardial infarction according to the specialty of the admitting physician. New England Journal of Medicine 1996;335(25): 1880-87.
39. Emmanuel EJ. Cost savings at the end of life: what do the data show? Journal of the. American Medical Association 1996;275(24):1907-14.
40. Schwartz WB. The inevitable failure of current cost-containment strategies: why they can provide only temporary relief. Journal of the American Medical Association 1987; 257(2):220-24.
41. Newhouse JP. An iconoclastic view of health cost containment. Health Affairs Supplement 1993; 152-71.
42. Hall MA and Anderson GF. Health insurers’ assessment of medical necessity. University of Pennsylvania Law Review 1992;140:1637-712.
43. Anderson GF. The courts and health policy: strengths and limitations. Health Affairs 1992;11 (4):95-110.
44. Hall MA and Anderson GF. Health insurers’ assessment of medical necessity. University of Pennsylvania Law Review 1992;140:1637-712.
45. Stone AA. Law’s influence on medicine and medical ethics. New England Journal of Medicine 1985;312(5):309-12.
46. Schuck PH. Malpractice liability and the rationing of care. Texas Law Review 1981;59:1421-27.
47. Havighurst CC. Prospective self-denial: can consumers contract today to accept health care rationing tomorrow? University of Pennsylvania Law Review 1992; 140 (5):1755-808.
48. Anderson GF. The courts and health policy: strengths and limitations. Health Affairs 1992; 11 (4): 95-110.
49. Fox DM and Schaffer DC. Semi-preemption in ERISA: legislative process and health policy. Anerican Journal of Tax Policy 1988;7(1):48-69.
50. McDonough RS. ERISA preemption of state-mandated provider laws. Duke Law Journal 1985:1194-1216.
51. Mariner WK. Liability for managed care decisions: the Employee Retirement Income Security Act (ERISA) and the uneven playing field. American Journal of Public Health 1996;86(6):863-69.
52. Marshall E. Gene therapy’s growing pains. Science 1995;269(5227):1050-55.
53. Marshall E. Less hype, more biology needed for gene therapy. Science 1995;270:1751.
54. Roush W. Counterfeit chromosomes for humans. Science 1997;276(5309):38-39.
55. Rosenfeld MA. Human artificial chromosomes get real. Nature Genetics 1997; 15(4):333-35.
56. Meitinger T. Widening the view. Nature Genetics 1997;15(3):224-25.
57. Randall T. First gene therapy for inherited hypercholesterolemia a partial success. Journal of the .American Medical .Association 1993;269(7):837-38.
58. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Medicine 1995;1(11):1148-54.
59. Murry CE, Kay MA, Bartosek T, et al. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. Journal of Clinical Investigation 1996;98(10):2209-17.
60. Takeshita S, Tsurumi T, et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Laboratory Investigation 1996; 75(4):487-501.
61. Castillo J, Davalos A, Noya M. Progression of ischaemic stroke and excitotoxicaminoacids. Lancet 1997;349(9045):79-83.
62. Solimena M, De Camilli P. Coxsackie viruses and diabetes. Nature Medicine 1995; 1 (1):2S-26.
63. Gottlieb AB. Immunopathogenesis of psoriasis: the road from bench to bedside is a 2-way street. Archives of Dermatology 1997;133(6):781-82.
64. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunology Today 1997; 18(7):335-43.
65. Onishi HR, Pelak BA, Gerckens LS, et al. Antibacterial agents that inhibit lipid A biosynthesis. Science 1996;274(5289):980-82.
66. Finch CE, Pike MC. Maximum lifespan predictions from the Gompertz mortality model. Journals of Gerontology, Series A, Biological and Medical Sciences 1996;51(3):B183-94.
67. Pennisi E. Premature aging gene discovered. Science 1996;272(5259):193-94.
68. Bodnar AG, Ouelette M, Frolkis M, et al. Extension of lifespan by introduction of telomerase into normal human cells. Science 1998; 279(5349): 349-52.
69. Vonnegut K. Welcome to the monkey house. New York: Delacorte, 1954.
70. “Overpopulation.'' Encyclopedia of Science Fiction. New York: St. Martin’s, 1993, 901-2.
71. Fanner P. Dayworld. New York: Putnam, 1985.